GlassScriptPhysician profile
Collina Afriyie
NPI 1316336449
$7,246.16
in general payments reported to CMS, 2019-2025
51 companies · $2,045 in 2025
The $2,045 reported for 2025 was more than what 91% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.64 · 2022: $1,109 · 2023: $2,091 · 2024: $1,985 · 2025: $2,045.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,107 · Education: $14.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,106.76 |
| Education | $14.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,865.00 | 2022-2025 | Ubrelvy, Qulipta, Duopa |
| Lilly USA, LLC | $958.22 | 2022-2025 | Kisunla, Amyvid, Emgality |
| Eisai INC. | $487.98 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $485.51 | 2022-2025 | Austedo Xr, Austedo, Austedo Xr |
| Pfizer INC. | $463.28 | 2022-2025 | |
| Lundbeck LLC | $304.01 | 2022-2025 | Vyepti, Rexulti |
| Neurelis, INC. | $233.01 | 2022-2025 | Valtoco |
| Ucb, INC. | $203.72 | 2022-2024 | Briviact, Rystiggo |
| Emd Serono, INC. | $194.61 | 2023-2025 | Mavenclad |
| Amgen INC. | $191.27 | 2022-2025 | Uplizna |
| Jazz Pharmaceuticals INC. | $177.50 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $167.26 | 2022-2025 | |
| Grifols USA, LLC | $122.88 | 2022-2025 | Gamunex-C |
| Harmony Biosciences LLC | $115.15 | 2023-2025 | Wakix |
| Alnylam Pharmaceuticals INC. | $70.92 | 2023-2025 | Amvuttra |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Collina Afriyie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.